Dec 19 (Reuters) - The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's MRK.N cholesterol pill and its cancer therapy, making them the latest additions to the fast-track program.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.